Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient.
Bodmer
Michael
M
Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland. bodmerm@uhbs.ch
Amico
Patrizia
P
Mihatsch
Michael J
MJ
Haschke
Manuel
M
Kummer
Oliver
O
Krähenbühl
Stephan
S
Mayr
Michael
M
D000368:Aged; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D004164:Diphosphonates / Q000494:pharmacology*; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D007668:Kidney / Q000473:pathology; D008297:Male; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000209:etiology*; D013997:Time Factors; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid